Compare COLD & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLD | ICUI |
|---|---|---|
| Founded | 1903 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.2B |
| IPO Year | 2018 | 1992 |
| Metric | COLD | ICUI |
|---|---|---|
| Price | $12.80 | $148.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $15.93 | ★ $183.60 |
| AVG Volume (30 Days) | ★ 7.6M | 236.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,607,407,000.00 | $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $107.00 |
| 52 Week High | $23.52 | $175.51 |
| Indicator | COLD | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 63.67 |
| Support Level | $10.51 | $141.10 |
| Resistance Level | $11.33 | $148.95 |
| Average True Range (ATR) | 0.45 | 3.94 |
| MACD | 0.32 | -0.34 |
| Stochastic Oscillator | 96.90 | 60.85 |
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 239 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.